Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluspirilene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluspirilene SCHEMBL15117504 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| Fluspirilene SCHEMBL28221293 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL904952 | 0.89 | OPRM1 (0.80) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| Fluspirilene SCHEMBL15821919 | 0.86 | OPRM1 (0.74) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL20305901 | 0.86 | OPRM1 (0.75) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL13964192 | 0.86 | OPRL1 (0.74) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| Fluspirilene SCHEMBL20958696 | 0.85 | DRD2 (0.74) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL10734578 | 0.84 | DRD2 (0.73) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL6402803 | 0.84 | OPRM1 (0.74) | OPRM1OPRK1OPRD1OPRL1DRD2 | |
| SCHEMBL11609724 | 0.84 | OPRM1 (0.72) | OPRM1OPRK1OPRD1OPRL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 42964 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-1999015161-A2 | INHIBITION OF PSYCHOSTIMULANT-INDUCED AND NICOTINE-INDUCED CRAVING | THE GENERAL HOSPITAL CORPORATION (US) | 1999-04-01 | — | — | WO | claimed |
| CN-1210460-A | Preparations stimulating nail growth | HOECHST AG (DE) | 1999-03-10 | — | — | CN | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| EP-0820682-A1 | NARROW BAND INTEGRATED APPLICATION NETWORK WITH MULTIFUNCTIONALITY | TELIA AB (SE) | 1998-01-28 | — | — | EP | claimed |
| WO-1996032820-A1 | NARROW BAND INTEGRATED APPLICATION NETWORK WITH MULTIFUNCTIONALITY | TELIA AB (SE) | 1996-10-17 | — | — | WO | claimed |
| EP-0308473-A1 | INFRARED IMMUNOLOGICAL DOSING | CNRS, Centre National de la Recherche Scientifique (FR) | 1989-03-29 | — | — | EP | claimed |
| WO-1988007684-A2 | INFRARED IMMUNOLOGICAL DOSING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1988-10-06 | — | — | WO | claimed |
| US-4430435-A | MIXING DOPAMINE RECEPTOR MATERIAL, RADIOALTIVE LABELED BINDER, PHOSPHATE BLOCKING AGENT AND MEASUREMENT OF RADIOACTIVITY | BURROUGHS WELLCOME CO. (US) | 1984-02-07 | — | — | US | claimed |
| US-4213963-A | Fluspirilene-containing compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-22 | — | — | US | claimed |
| US-4197288-A | Neuroleptic radioreceptor assay method and kit | BURROUGHS WELLCOME CO. (US) | 1980-04-08 | — | — | US | claimed |